Raplixa

RSS

Withdrawn

This medicine's authorisation has been withdrawn

human fibrinogen / human thrombin
MedicineHumanWithdrawn

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 19 March 2018, the European Commission withdrew the marketing authorisation of Raplixa (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mallinckrodt Pharmaceuticals Ireland Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Raplixa was granted marketing authorisation in the EU on 19 March 2015 as supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for Raplixa is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Product information

български (BG) (1.37 MB - PDF)

Ara

español (ES) (802.94 KB - PDF)

Ara

čeština (CS) (1.11 MB - PDF)

Ara

dansk (DA) (667.49 KB - PDF)

Ara

Deutsch (DE) (874.95 KB - PDF)

Ara

eesti (ET) (792.45 KB - PDF)

Ara

ελληνικά (EL) (1.57 MB - PDF)

Ara

français (FR) (907.5 KB - PDF)

Ara

hrvatski (HR) (816.84 KB - PDF)

Ara

italiano (IT) (811.21 KB - PDF)

Ara

latviešu (LV) (1.12 MB - PDF)

Ara

lietuvių (LT) (903.17 KB - PDF)

Ara

magyar (HU) (1.1 MB - PDF)

Ara

Malti (MT) (1.21 MB - PDF)

Ara

Nederlands (NL) (752.15 KB - PDF)

Ara

polski (PL) (1.17 MB - PDF)

Ara

português (PT) (675.6 KB - PDF)

Ara

română (RO) (854.03 KB - PDF)

Ara

slovenčina (SK) (1.16 MB - PDF)

Ara

slovenščina (SL) (1.09 MB - PDF)

Ara

suomi (FI) (743.95 KB - PDF)

Ara

svenska (SV) (786.13 KB - PDF)

Ara

Íslenska (IS) (769.69 KB - PDF)

Ara

norsk (NO) (739.34 KB - PDF)

Ara
Latest procedure affecting product information:IB/0021/G
19/03/2018
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (495.82 KB - PDF)

Ara

español (ES) (458.22 KB - PDF)

Ara

čeština (CS) (486.16 KB - PDF)

Ara

dansk (DA) (473.24 KB - PDF)

Ara

Deutsch (DE) (486.73 KB - PDF)

Ara

eesti (ET) (457.96 KB - PDF)

Ara

ελληνικά (EL) (522.16 KB - PDF)

Ara

français (FR) (458.01 KB - PDF)

Ara

hrvatski (HR) (480.96 KB - PDF)

Ara

italiano (IT) (485.25 KB - PDF)

Ara

latviešu (LV) (489.37 KB - PDF)

Ara

lietuvių (LT) (473.19 KB - PDF)

Ara

magyar (HU) (476.56 KB - PDF)

Ara

Malti (MT) (509.39 KB - PDF)

Ara

Nederlands (NL) (458.08 KB - PDF)

Ara

polski (PL) (485.34 KB - PDF)

Ara

português (PT) (901.52 KB - PDF)

Ara

română (RO) (48.88 KB - PDF)

Ara

slovenčina (SK) (478.28 KB - PDF)

Ara

slovenščina (SL) (476.99 KB - PDF)

Ara

suomi (FI) (457.79 KB - PDF)

Ara

svenska (SV) (21.78 KB - PDF)

Ara

Íslenska (IS) (484.51 KB - PDF)

Ara

norsk (NO) (457.37 KB - PDF)

Ara

Product details

Name of medicine
Raplixa
Active substance
  • human fibrinogen
  • human thrombin
International non-proprietary name (INN) or common name
  • human fibrinogen
  • human thrombin
Therapeutic area (MeSH)
Hemostasis, Surgical
Anatomical therapeutic chemical (ATC) code
B02BC30

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Supportive treatment where standard surgical techniques are insufficient for improvement of haemostasis.

Raplixa must be used in combination with an approved gelatin sponge.

Raplixa is indicated in adults over 18 years of age.

Authorisation details

EMA product number
EMEA/H/C/002807
Marketing authorisation holder
Mallinckrodt Pharmaceuticals Ireland Limited

College Business Technology Park
Cruiserath
Blanchardstown
Dublin 15
Ireland

Marketing authorisation issued
19/03/2015
Withdrawal of marketing authorisation
19/03/2018
Revision
6

Assessment history

This page was last updated on

Share this page